Form 4: Equillium Inc. Director Martha J. Demski Reports Stock Option Grant

Director Martha J. Demski reports the acquisition of stock options in Equillium, Inc.

Summary

• On May 22, 2024, Martha J. Demski, a director of Equillium, Inc., was granted stock options to purchase 20,000 shares of common stock.
• The exercise price of the stock options is $1.43 per share.
• The options vest in twelve equal monthly installments starting on May 22, 2024, and will be fully vested by the date of the Issuer's annual meeting of stockholders following the grant date.
• The expiration date for these options is May 22, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and generally viewed as a positive incentive for the director, aligning their interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options as part of their compensation strategy to align the interests of their leadership with shareholder value creation.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates